RxDoctor Payments Data

Terence Dunn, MD

Clinical Cardiac Electrophysiology · Birmingham, ALNPI 1295145373

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (33.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 35.0% of the total. 2025 is the largest year on record at $24,009, 3.2 times the $7,500 reported in 2020.

$72,525in general payments, 2019–2025

Across 273 payments — averaging $265.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$25K
  • Medtronic$18K
  • Boston Scientific$13K
  • Biotronik Inc.$9K
  • Biosense Webster, Inc.$5K
  • Medical Device Business Services, Inc.$1K
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$17,79625%
  • Grants$24,50034%
  • Travel & lodging$19,08626%
  • Food & beverage$11,14315%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,525 in reported general payments places this provider in the 85th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

See all clinical cardiac electrophysiology providers in Alabama

Medicare billing

Part B allowed, 2024
$153,679
Medicare patients
288
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$72,066
EntrestoSacubitril/Valsartan16$13,337
Flecainide Acetate21$617
Metoprolol Succinate27$375
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$314
Atorvastatin Calcium14$301
Carvedilol23$147
Amlodipine Besylate11$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$189$72,06697 claims
NovartisEntresto$150$13,33716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

Other clinical cardiac electrophysiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →